Skip to main content
. 2024 Mar 15;25(1):40. doi: 10.1186/s10194-024-01747-w

Table 3.

Cost-effectiveness results at 10-year follow-up

Comparators Cost Effectiveness ICER
MD QALYs
Episodic migraine
 Topiramate + BSC €17,059 1,049 5.8839 -
 Erenumab + BSC €21,479 877 6.1150 €26/MD avoided
€19,122/QALY gained
Chronic migraine
 Placebo + BSC €24,921 2,100 4.5016 -
 Erenumab + BSC €26,734 1,532 5.2578 €3/MMD avoided
€2,398/QALY gained

BSC best supportive care, ICER incremental cost-effectiveness ratio, MD migraine days, QALYs quality-adjusted life years